{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:28:16Z","timestamp":1790504896459,"version":"4.1.0"},"reference-count":104,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-19 pandemic and has included all potential approaches for providing the global community with safe and efficient vaccine candidates in the shortest possible timeframe. Viral vectors have played a central role especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses and lentiviruses have been subjected to vaccine development. Self-amplifying RNA virus vectors have been utilized for lipid nanoparticle-based delivery of RNA as COVID-19 vaccines. Several adenovirus-based vaccine candidates have elicited strong immune responses in immunized animals and protection against challenges in mice and primates has been achieved. Moreover, adenovirus-based vaccine candidates have been subjected to phase I to III clinical trials. Recently, the simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was approved for use in humans in the UK.<\/jats:p>","DOI":"10.3390\/v13020317","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T09:06:10Z","timestamp":1613725570000},"page":"317","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Viral Vectors for COVID-19 Vaccine Development"],"prefix":"10.3390","volume":"13","author":[{"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[{"name":"PanTherapeutics, CH1095 Lutry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"ref_1","unstructured":"(2020, April 28). Global Health Policy. Available online: https:\/\/www.google.com\/covid19-map."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.prrv.2004.07.009","article-title":"The chronology of the 2002\u20132003 SARS mini pandemic","volume":"5","author":"Cherry","year":"2004","journal-title":"Paediatr. Resp. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Aleanizi, F.S., Mohmed, N., Alqahtani, F.Y., and El Hadi Mohamed, R.A. (2017). Outbreak of Middle east respiratory syndrome coronavirus in Saudi Arabia: A retrospective study. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-016-2137-3"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2020). Coronavirus Pandemic\u2014Therapy and Vaccines. Biomedicines, 8.","DOI":"10.3390\/biomedicines8050109"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0298-180","article-title":"Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity","volume":"18","author":"Schiedner","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus vectored COVID-19 vaccine confers protection from SARS-CoV-2 challenge in rhesus macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1007\/s00253-018-9091-5","article-title":"Process optimization for the rapid production of adenoviral vectors for clinical trials in a disposable bioreactor system","volume":"102","author":"Chen","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_9","first-page":"161","article-title":"Poxviruses as vectors for cancer immunotherapy","volume":"6","author":"Kwak","year":"2003","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gomez, C.E., Perdiguero, B., Jimenez, V., Filali, A., Haddad, E.K., Quakkelaar, E.D., Delaloye, J., Harari, A., Roger, T., and Dunhen, T. (2012). Ssytems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV\/AIDS of Clade C. PLoS ONE, 7.","DOI":"10.1371\/annotation\/09c18b10-8433-4d64-be1c-61e578cc088b"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/517614","article-title":"Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1","volume":"195","author":"Kreijtz","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development","volume":"197","author":"Volz","year":"2017","journal-title":"Adv. Virus Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1521-2254(200009\/10)2:5<308::AID-JGM131>3.0.CO;2-3","article-title":"Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy","volume":"2","author":"Vigna","year":"2000","journal-title":"J. Gen. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/hgtb.2017.086","article-title":"Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines","volume":"28","author":"Manceur","year":"2017","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.exphem.2006.02.005","article-title":"Lentiviral vectors pseudotyped with murine ecotropic envelope: Increased biosafety and convenience in preclinical research","volume":"34","author":"Schambach","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coph.2015.08.003","article-title":"Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells","volume":"24","author":"Verhoeyen","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Xu, K. (2011). Gene Regulatable Lentiviral Vector System. Viral Gene Therapy, Intech Open.","DOI":"10.5772\/1011"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12033-017-0006-y","article-title":"Design of a Lentiviral Vector for the Inducible Expression of MYC: A New Strategy for Construction Approach","volume":"59","author":"Tokgun","year":"2017","journal-title":"Mol. Biotechnol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/fvl-2016-0028","article-title":"Self-replicating RNA viral vectors in vaccine development and gene therapy","volume":"11","author":"Lundstrom","year":"2016","journal-title":"Future Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1002\/j.1460-2075.1995.tb00266.x","article-title":"Rescue of measles viruses from cloned DNA","volume":"14","author":"Radecke","year":"1995","journal-title":"EMBO J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1128\/JVI.73.6.4823-4828.1999","article-title":"A recombinant measles virus expressing hepatitis B surface antigen induces humoral responses in genetically modified mice","volume":"73","author":"Singh","year":"1999","journal-title":"J. Virol."},{"key":"ref_23","unstructured":"Knipe, D.M., and Howley, P.M. (2007). Rhabdoviridiae. Fields\u2019 Virology, Wolters Kluwer Health\/Lippincott Williams & Wilkins. [5th ed.]."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/nprot.2013.094","article-title":"Design and generation of recombinant rabies virus vectors","volume":"8","author":"Osakada","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.virusres.2012.11.007","article-title":"Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression","volume":"171","author":"An","year":"2013","journal-title":"Virus Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/neuro.05.001.2009","article-title":"Dual transneural tracing in the rat entorhoinal-hippocampal circuit by intracerebral injection of recombinant rabies virus vectors","volume":"3","author":"Ohara","year":"2009","journal-title":"Front. Neuroanat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12981-017-0179-2","article-title":"Development of an HIV vaccine using vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses","volume":"14","author":"Racine","year":"2017","journal-title":"AIDS Res. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1348-0421.2003.tb03424.x","article-title":"Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system","volume":"47","author":"Ito","year":"2003","journal-title":"Microbiol. Immunol."},{"key":"ref_29","first-page":"513","article-title":"Vaccinia virus-free recovery of vesicular stomatitis virus","volume":"3","author":"Harty","year":"2001","journal-title":"J. Mol. Microbiol. Biotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/nbt1291-1356","article-title":"A new generation of animal cell expression vectors based on the Semliki Forest virus replicon","volume":"9","author":"Liljestrom","year":"1991","journal-title":"Biotechnology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1126\/science.2922607","article-title":"Sindbis virus: An efficient, broad host range vector for gene expression in animal cells","volume":"243","author":"Xiong","year":"1989","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0042-6822(89)90526-6","article-title":"In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: Analysis of a viable deletion mutant","volume":"171","author":"Davis","year":"1989","journal-title":"Virology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2020). Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses, 12.","DOI":"10.3390\/v12111324"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Safronetz, D., Mire, C., Rosenke, K., Feldmann, F., Haddock, E., Geissbert, T., and Feldmann, H. (2015). A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003736"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1016\/j.vaccine.2018.05.095","article-title":"A recombinant virus vaccine that protects both against Chikungunya and Zika virus infections","volume":"36","author":"Chattopadhyay","year":"2018","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sullivan, N.J., Geisbert, T.W., Geisbert, J.B., Shedlock, D.J., Xu, L., Lamoreaux, L., Custers, J.H.H.V., Popernack, P.M., Yang, Z.-Y., and Pau, M.G. (2006). Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030177"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Longini","year":"2015","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cell.2020.03.011","article-title":"A vaccine against Ebola virus","volume":"181","year":"2020","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"King, R.G., Silva-Sanchez, A., Peel, J.N., Botta, D., Meza Perez, S., Allie, S.R., Schultz, M.D., Liu, M., Bradley, J.E., and Qiu, S. (2020). Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice. bioRxiv.","DOI":"10.1101\/2020.10.10.331348"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters","volume":"26","author":"Tostanoski","year":"2020","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCov-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"Lambe","year":"2020","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.chom.2020.12.010","article-title":"Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models","volume":"29","author":"Ku","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform","volume":"11","author":"Chiuppesi","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arriaza, J., Garaigorta, U., P\u00e9rez, P., L\u00e1zaro-Fr\u00edas, A., Zamora, C., Gastaminza, P., Del Fresno, C., Casasnovas, J.M., Sorzano, C.\u00d3.S., and Sancho, D. (2021). COVID-19 vaccine candidates based on modified vaccinia Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and fully efficacy in mice. J. Virol.","DOI":"10.1128\/JVI.02260-20"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Sun, W., McCroskery, S., Liu, W.C., Leist, S.R., Liu, Y., Albrecht, R.A., Slamanig, S., Oliva, J., Amanat, F., and Sch\u00e4fer, A. (2020). A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines, 8.","DOI":"10.1101\/2020.07.30.229120"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"103132","DOI":"10.1016\/j.ebiom.2020.103132","article-title":"Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate","volume":"62","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"32657","DOI":"10.1073\/pnas.2014468117","article-title":"A highly immunogenic and effective measles virus-based Th1-biased COVID-19 Vaccine","volume":"117","author":"Auste","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice","volume":"28","author":"Brett","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","article-title":"A single dose of recombinant VSV-\u2206G-spike provides protection against SARS-CoV-2 challenge","volume":"11","author":"Tamir","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibodies in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_54","unstructured":"(2021, February 09). VBI Announces Progress of Coronavirus Vaccine Program. Available online: www.vbivaccines.com\/wire\/coronavirus-vaccine-program-update\/."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Loes, A.N., Gentles, L.E., Greaney, A.J., Crawford, K.H.D., and Bloom, J.D. (2020). Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice. Viruses, 12.","DOI":"10.1101\/2020.08.12.248823"},{"key":"ref_56","unstructured":"(2021, January 14). Draft Landscape of COVID-19 Vaccines. Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3389\/fimmu.2020.01959","article-title":"Combating COVID-19: MVA vector vaccines applied to the respiratory tract as promising toward protective immunity in the lung","volume":"11","author":"Fleige","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/CVI.00662-13","article-title":"Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity","volume":"21","author":"Kirchmeier","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years and older: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_61","unstructured":"(2021, January 22). Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04526990."},{"key":"ref_62","unstructured":"(2021, January 22). Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04540419."},{"key":"ref_63","unstructured":"(2021, January 22). A Study of Ad26.COV2.S in Adults (COVID-19), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04436276."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A.M., Stoop, J., Tete, S., Van Damme, W., and Leroux-Roels, I. (2021). Interim Results of a Phase 1-2a Trial of Ad26.COV.S Covid-19 Vaccine. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2034201"},{"key":"ref_65","unstructured":"(2021, January 22). A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04505722."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"(2021, January 22). A study of the Ad26.COV2.S Vaccine Candidate for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adults. Available online: https:\/\/doi.org\/10.1186\/ISRCTN14722499.","DOI":"10.1186\/ISRCTN14722499"},{"key":"ref_67","unstructured":"(2021, January 22). Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine against COVID-19 (RESIST), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04530396."},{"key":"ref_68","unstructured":"(2021, January 22). Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine against COVID-19 in Belarus, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04564716."},{"key":"ref_69","unstructured":"(2021, January 22). Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine against COVID-19 in Venezuela, Available online: https:\/\/clinicaltrials.gov\/ct2\/\/show\/NCT04642339."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Logunov, D.Y., Dolzhikova, I.V., Shcheblyakov, D.V., Tukhavatulin, A.Y., Zubkova, O.V., Dzharullaeva, A.S., Kovyrshina, A.V., Lubenets, N.L., Grousova, D.M., and Erokhova, A.S. (2020). Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19: An interim analysis of a randomised controlled phase 3 in Russia. Lancet.","DOI":"10.1016\/S0140-6736(21)00234-8"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/d41586-020-02386-2","article-title":"Russia\u2019s fast-track coronavirus vaccine draws outrage over safety","volume":"584","author":"Callaway","year":"2020","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAsOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2 single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_73","unstructured":"(2021, January 22). A Phase 2\/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in Healthy UK Volunteers, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04400838."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"ref_75","unstructured":"(2021, January 22). Phase III Double-Blind, Placebo-Controlled Study of AZD1222 for the Prevention of COVID-19 in Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04516746."},{"key":"ref_76","unstructured":"(2021, January 22). AZD1222 Vaccine for the Prevention of COVID-19, Available online: https:\/\/clinicaltriasl.gov\/ct\/show\/NCT04540393."},{"key":"ref_77","unstructured":"(2021, January 22). A Phase III Study to Investigate a Vaccine against COVID-19. Available online: https:\/\/doi.org\/10.11186\/ISRCTN89951424."},{"key":"ref_78","unstructured":"(2021, January 22). A Phase 2\/3 Observer-Blind, Randomized, Controlled Study to Determine the Safety and Immunogenicity of Covshield (COVID-19) in Healthy Indian Adults. Available online: http:\/\/ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=46186&EncHid=&userName=covid-19%20vaccine."},{"key":"ref_79","unstructured":"(2021, January 25). Regulatory Approval of COVID-19 Vaccine AstraZeneca\u2014GOV.UK, Available online: www.gov.uk."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_81","unstructured":"(2021, January 22). Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S against COVID-19, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04569383."},{"key":"ref_82","unstructured":"(2021, January 25). A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04639466."},{"key":"ref_83","unstructured":"(2021, January 22). Immunity and Safety of Covid-19 Synthetic Minigene Vaccine, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276896."},{"key":"ref_84","unstructured":"(2021, February 09). Merck Discontinues Development of SARS-CoV-2\/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates. Available online: www.merck.com\/news\/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates\/."},{"key":"ref_85","unstructured":"(2021, February 09). Merck and IAVI Discontinue Development of COVID-19 Vaccine Candidate V590. Available online: www.iavi.org\/news-resources\/press-releases\/2021\/merck-and-iavi-discontinue-development-of-covid-19-vaccine-candidate-v590."},{"key":"ref_86","unstructured":"(2021, January 25). Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04608305."},{"key":"ref_87","unstructured":"(2021, January 25). A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1). ChiCTR2000037782. Available online: www.chictr.org.cn\/showprojen.aspx?proj=55421."},{"key":"ref_88","unstructured":"(2021, January 25). A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1). ChiCTR2000039715. Available online: www.chictr.org.cn\/showprojen.aspx?proj=63754."},{"key":"ref_89","unstructured":"(2021, January 22). Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (COVID-19-101), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04497298."},{"key":"ref_90","unstructured":"(2021, January 22). Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04569786."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1177\/0194599820933170","article-title":"Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review","volume":"163","author":"Higgins","year":"2020","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Phillips, N., Cyranoski, D., and Mallapaty, S. (2020). A leading coronavirus vaccine trial is on hold: Scientists react. Nature.","DOI":"10.1038\/d41586-020-02594-w"},{"key":"ref_93","unstructured":"(2021, January 25). Global Clinical Trials of COVID-19 Vaccine Resume. Available online: https:\/\/www.ox.ac.uk\/news\/2020-11-23-global-clinical-trials-covid-19-vaccine-resume."},{"key":"ref_94","unstructured":"Al Idrus, A. (2021, January 25). Russia Posts 91.4 % Efficacy for COVID-19 Vaccine after Jumping the Gun to Approval. Available online: https:\/\/www.fiercebiotech.com\/biotech\/russia-posts-91-efficacy-for-covid-19-vaccine-after-jumping-gun-to-approval."},{"key":"ref_95","unstructured":"Balfour, H. (2020). AstraZeneca to test combination of AZD1222 and Sputnik V vaccines. Eur. Pharmaceutical Rev."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Spencer, A.J., McKay, P.F., Belij-Rammerstorfer, S., Ulaszewska, M., Bissett, C.D., Hu, K., Samnuan, K., Wright, D., Sharpe, H.R., and Gilbride, C. (2021). Heterologous vaccination regimens with self-amplifying RNA and Adenoviral 2 COVID vaccines induce superior immune responses than single dose vaccine 3 regimens in mice. bioRxiv.","DOI":"10.1101\/2021.01.28.428665"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Ledford, H. (2021). Could mixing COVID vaccines boost immune response?. Nature.","DOI":"10.1038\/d41586-021-00315-5"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"(2021, January 25). Clinical Trial to Assess the Safety of a Coronavirus Vaccine in Healthy Men and Women. Available online: https:\/\/doi.org\/10.1186\/ISRCTN17072692.","DOI":"10.1186\/ISRCTN17072692"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2002106","DOI":"10.2807\/1560-7917.ES.2020.26.1.2002106","article-title":"Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020","volume":"26","author":"Leung","year":"2021","journal-title":"Euro Surveill."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15585\/mmwr.mm7003e2","article-title":"Emergence of SARS-CoV-2 B.1.1.7 Lineage\u2014United States, 29 December 2020\u201312 January 2021","volume":"70","author":"Galloway","year":"2021","journal-title":"MMWR Morb. Mortal Wkly Rep."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C.O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., and Lieberman, J.A. (2021). mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. bioRxiv.","DOI":"10.1101\/2021.01.15.426911"},{"key":"ref_102","unstructured":"Emary, K.R.W., Golubchik, T., Lay, P.K., Ariani, C.V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., and Charlton, S. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012\/01 (B.1.1.7). Soc. Sci. Electron. Publ."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Mahase, E. (2021). Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. Br. Med. J., 372.","DOI":"10.1136\/bmj.n296"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Xie, X., Zou, J., Fontes-Garfias, C.R., Xia, H., Swanson, K.A., Cutler, M., Cooper, D., Menachery, V.D., Scott Weaver, S., and Dormitzer, P.R. (2021). Neutralization of N501Y mutant SARS-CoV-2 by BNT162b vaccine-elicited sera. bioRxiv.","DOI":"10.1101\/2021.01.07.425740"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/2\/317\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:26:03Z","timestamp":1760160363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/2\/317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":104,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["v13020317"],"URL":"https:\/\/doi.org\/10.3390\/v13020317","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]}}}